215 related articles for article (PubMed ID: 20708938)
1. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.
Sellers RP; Alexander LD; Johnson VA; Lin CC; Savage J; Corral R; Moss J; Slugocki TS; Singh EK; Davis MR; Ravula S; Spicer JE; Oelrich JL; Thornquist A; Pan CM; McAlpine SR
Bioorg Med Chem; 2010 Sep; 18(18):6822-56. PubMed ID: 20708938
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action.
Alexander LD; Sellers RP; Davis MR; Ardi VC; Johnson VA; Vasko RC; McAlpine SR
J Med Chem; 2009 Dec; 52(24):7927-30. PubMed ID: 20014866
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90.
Kunicki JB; Petersen MN; Alexander LD; Ardi VC; McConnell JR; McAlpine SR
Bioorg Med Chem Lett; 2011 Aug; 21(16):4716-9. PubMed ID: 21764310
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines.
Pan PS; Vasko RC; Lapera SA; Johnson VA; Sellers RP; Lin CC; Pan CM; Davis MR; Ardi VC; McAlpine SR
Bioorg Med Chem; 2009 Aug; 17(16):5806-25. PubMed ID: 19643615
[TBL] [Abstract][Full Text] [Related]
5. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
[TBL] [Abstract][Full Text] [Related]
6. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
Ardi VC; Alexander LD; Johnson VA; McAlpine SR
ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines.
Otrubova K; Lushington G; Vander Velde D; McGuire KL; McAlpine SR
J Med Chem; 2008 Feb; 51(3):530-44. PubMed ID: 18186604
[TBL] [Abstract][Full Text] [Related]
8. C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Apr; 13(16):4627-31. PubMed ID: 25711919
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
Jia JM; Liu F; Xu XL; Guo XK; Jiang F; Cherfaoui B; Sun HP; You QD
Bioorg Med Chem Lett; 2014 Mar; 24(6):1557-61. PubMed ID: 24582477
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and cytotoxicity of novel sansalvamide A derivatives.
Carroll CL; Johnston JV; Kekec A; Brown JD; Parry E; Cajica J; Medina I; Cook KM; Corral R; Pan PS; McAlpine SR
Org Lett; 2005 Aug; 7(16):3481-4. PubMed ID: 16048322
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis.
Gümus M; Ozgur A; Tutar L; Disli A; Koca I; Tutar Y
Curr Pharm Biotechnol; 2016; 17(14):1231-1245. PubMed ID: 27804852
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.
Shao LD; Su J; Ye B; Liu JX; Zuo ZL; Li Y; Wang YY; Xia C; Zhao QS
J Med Chem; 2017 Nov; 60(21):9053-9066. PubMed ID: 29019670
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
18. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.
Mettu A; Talla V; Bajaj DM; Subhashini NJP
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900063. PubMed ID: 31411362
[TBL] [Abstract][Full Text] [Related]
20. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
